Ben Markman

ADJUNCT SENIOR RESEARCH FELLOW, Hudson Institute - Centre for Cancer Research

Emailben.markman@monash.edu

Research activity per year

If you made any changes in Pure these will be visible here soon.

Network

Recent external collaboration on country level. Dive into details by clicking on the dots or

1 Finished
22 Active

A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharamcokinetics, and Antitumor Activity of AK119 in Combination with AK104 in Subjects with Advanced or Metastatic Solid Tumors.
Markman, B. & Hawkins, C.
24/02/21 → 31/12/26
Project: Research
A Multicenter, Open-label, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of YH003 in combination with Toripalimab (anti-PD-1mAb) in Subjects with Advanced Solid Tumors.
Markman, B. & Hawkins, C.
20/10/20 → 31/12/22
Project: Research
PACIFIC-Real World: First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (D4194R00005)
Markman, B. & Baker, E.
17/10/19 → 31/12/24
Project: Research
A Phase 1a/1b Multicentre, Open label, Dose escalation and Dose expansion Study to Evaluate the Safety, Pharmacokinetics, And Antitumor Activity of Ak104 in Subjects with Advanced Solid Tumours
Markman, B.
20/09/19 → 19/09/24
Project: Research
A Phase la/lb, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors
Day, D. & Markman, B.
6/06/19 → 5/06/24
Project: Research

17 Article
3 Chapter (Book)
1 Meeting Abstract

Recruitment, outcomes and toxicity trends in phase I oncology trials: six-year experience in a large institution
Menon, S., Davies, A., Frentzas, S., Hawkins, C-A., Segelov, E., Day, D. & Markman, B., Nov 2020, In : Asia-Pacific Journal of Clinical Oncology. p. 154-154 1 p.
Research output: Contribution to journal › Meeting Abstract › Other › peer-review
A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer
Alamgeer, M., Neil Watkins, D., Banakh, I., Kumar, B., Gough, D. J., Markman, B. & Ganju, V., 1 Apr 2018, In : Investigational New Drugs. 36, 2, p. 288-298 11 p.
Research output: Contribution to journal › Article › Research › peer-review

14 Citations (Scopus)
Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC
McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., Harris, D. L., Stagg, R. J., Kapoun, A. M., Xu, L. & Hughes, B. G. M., 1 Feb 2018, In : Targeted Oncology. 13, 1, p. 89-98 10 p.
Research output: Contribution to journal › Article › Research › peer-review

19 Citations (Scopus)
mTOR inhibition beyond rapalogs
Markman, B., Serra, V. & Tabernero, J., 2016, mTOR Inhibition for Cancer Therapy: Past, Present and Future. Mita, M., Mita, A. & Rowinsky, E. K. (eds.). Paris France: Springer, p. 251 - 27 25 p.
Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Research › peer-review
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors
Papadopoulos, K. P., Tabernero, J., Markman, B., Patnaik, A., Tolcher, A. W., Baselga, J., Shi, W., Egile, C., Ruiz-Soto, R., Laird, A. D., Miles, D. & LoRusso, P. M., 2014, In : Clinical Cancer Research. 20, 9, p. 2445 - 2456 12 p.
Research output: Contribution to journal › Article › Research › peer-review

Open Access

67 Citations (Scopus)